Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

BiOasis Technologies Inc V.BTI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  BIOAF

biOasis Technologies Inc is a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. Its focus is to address unmet medical needs with its proprietary Transcend Platform.
Price: $1.25 | Change: $0.00 | %Change: 0.00%
Volume: 29,320 | Day High/Low: 1.25/1.22 | 52 Week High/Low: 1.35/0.67
View modes: 
3.5 stars

RE:RE:RE:A Few Thoughts about The Jrstocks Analyst Report

The fact is, value_investor69, we simply don't know where biOasis is at with MTfp-TZM. We just don't. It's gone quiet. But yet, biOasis is not backing away from its stated expectation to achieve IND...read more
2.5 stars

RE:Countdown: 36 days

36 days, Sir_Holler? You say, "perhaps in the next 36 days" and then you engage in a countdown? I really don't like to think that people are stupid or crazy, let alone specualte aloud about that, but...read more
3.5 stars

Countdown: 36 days

The report anticipates 1 or 2 long-term licensing deals, perhaps in the next 36 days, where the stock could rise to more closely reflect their $3.65 valuation. BTI not only paid for the report but...read more
0 stars

RE:RE:A Few Thoughts about The Jrstocks Analyst Report

Why do you think BIOASIS did not decide to work on fusion proteins for Herceptin before anything else?  rate and reply
0 stars

RE:A Few Thoughts about The Jrstocks Analyst Report

I should make a small clarification/addition in the 1st line of the 4th paragraph in my previous post. Currently, the line reads, "But if MTfp-TZM (Transcend/Herceptin fusion protein) works in both...read more
3.5 stars

A Few Thoughts about The Jrstocks Analyst Report

I'm not "stroking out" about this analyst's report as darnit opines. He has incorrectly predicted my reaction to it. But the report is flawed to a degree, in my opinion. It was written by somebody who...read more
0 stars

RE:RE:RE:RE:The 25 Million Dollar Question?

This is just the boarding of the boat. However at this price you might not want to miss it. Compare to a company that has already sailed GEVA with a 4.35B market cap compared to BTI with 55.92M...read more
0 stars

RE:RE:RE:The 25 Million Dollar Question?

amillionorbust wrote: Because a true valuation on the model this analyst suggests is just too ridiculous to write. Look at the ridicule some posters here received when they actually crunched the data....read more
0 stars

RE:RE:A Little Vancouver Biotech Does a Deal

They currently have 10 more drugs in their pipeline at 164 million plus per program. Not bad. . Zymeworks will receive an initial upfront payment, as well as an equity investment from Celgene...read more
0 stars

RE:A Little Vancouver Biotech Does a Deal

the one that is more interesting is the one zymeworks did with eli lilly just because of the disclosure there.  Zymeworks has granted Lilly a worldwide license to the Azymetric™ platform to develop...read more
0 stars

RE:A Little Vancouver Biotech Does a Deal

not that it matters but have a look at their address and bti's old address. 1 floor apart.   drj!  rate and reply
0 stars

A Little Vancouver Biotech Does a Deal

Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks Forbes 1/21/2015 ....None of Zymeworks' internally developed drug candidates have made it yet into clinical trials, so it has much to...read more
0 stars

RE:The 25 Million Dollar Question?

Think about it! Not only is the patent extended for an additional 20 years, but will be prescribed much more often because of its ability to get through the BBB and treat otherwise untreatable...read more
3 stars

RE:RE:The 25 Million Dollar Question?

Because a true valuation on the model this analyst suggests is just too ridiculous to write. Look at the ridicule some posters here received when they actually crunched the data. It does not take too...read more
5 stars

NEWS OUT NEWS OUT!!!!!!!!

.............................................looking back at most of my posts....my spelling and grammer are a disgrace to the english language. ....and a disgrace to mankind!.....  rate and reply
0 stars

RE:The 25 Million Dollar Question?

J.d....then why dud this sobcalled analyst write 25million.....and why dud bioasis allow that to be published...i agree with you...this is why all the uproar .....if its a typo...lets clarify that.......read more
3.5 stars

The 25 Million Dollar Question?

This analysts and some posters here are saying, perhaps as an honest mistake, that deals for Transcend would top out at $25 million. Herceptin sales are About $7 billion per year. That's almost $20...read more
0 stars

RE:Analyst Report

So is the consensus here that it was a typo on the $25 million versus more probable $250 million? I doubt it's a typo.  But neither do I think it will turn out to be accurate.  I'll just leave it as...read more
0 stars

Analyst Report

So is the consensus here that it was a typo on the $25 million versus more probable $250million? If that's the case it's pretty weak if management missed that on the proof read. I suspect it was the...read more
0 stars

its official

synageva hits new hi of $120+ still dont know how they plan on showing efficacy in the cns. they have a new hi and we have a new report that some people here just can't understand. oh wel................read more